Argenx reports positive Phase 2 results for FB102 in celiac disease

Argenx, a biotechnology company, announced positive topline results from a Phase 2 study of FB102 in adults with celiac disease. The study tested a first-in-class CD122 inhibitor to reduce gluten-related intestinal damage. This explainer outlines what happened, who may be affected, and practical next steps, with sources linked for key claims.

What happened in the study

Argenx reported that FB102 met its primary endpoint in a Phase 2 trial evaluating changes in the villus-to-crypt ratio (Vh:Cd), a histology measure of intestinal lining health used in celiac disease. The study findings are described as statistically significant, indicating a treatment effect versus placebo. FB102 is described as a first-in-class inhibitor targeting CD122, a component of the immune system involved in immune cell signaling. The company notes that positive topline results followed the acquisition of Forte Biosciences in August 2026.

Who is affected or may benefit

The potential beneficiaries are adults with active celiac disease who experience gluten-induced intestinal damage. The study focuses on changes in intestinal tissue health, which researchers use as a proxy for disease activity. It is not stated that FB102 is approved for general use; the results described are topline (early-stage) findings from a Phase 2 trial and would need confirmation in larger, later-stage studies before any new therapy could be approved for routine treatment.

Practical next steps for patients and clinicians

If you are a patient or clinician, consider the following: (1) await detailed trial results and peer-reviewed publication for full safety and efficacy data; (2) monitor regulatory announcements for plans to advance FB102 to Phase 3 trials; (3) continue current, established celiac disease management, including gluten-free diet and medical guidance; (4) discuss emerging therapies with a healthcare provider once more data are available. The company’s press release indicates development progress but does not imply immediate availability or approval for use outside a trial setting.

Limits of the information and open questions

Key limitations: topline results are initial and may change with full data and longer follow-up; the safety profile in Phase 2 may require confirmation in larger studies; the treatment’s practical use, dosing. Cost are not addressed in the summary. Open questions include whether FB102 will proceed to Phase 3, what long-term effects might occur, how it compares with existing celiac disease therapies, and what regulatory timelines might look like.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.